Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

The therapeutic potential of exosomes derived from different cell sources in liver diseases

Pan Y., Tan WF., Yang MQ., Li JY., Geller DA.

Narrative Review, published in Am J Physiol Gastrointest Liver Physiol (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Am J Physiol Gastrointest Liver Physiol (2022)
Reported sample size
—
Source database
Europe PMC
PMID
35107032
PMCID
PMC8917924
DOI
10.1152/ajpgi.00054.2021
Citations
14

Abstract (original English)

Exosomes are small nanovesicles with a size of approximately 40-120 nm that are secreted from cells. They are involved in the regulation of cell homeostasis and mediate intercellular communication. In addition, they carry proteins, nucleic acids, and lipids that regulate the biological activity of receptor cells. Recent studies have shown that exosomes perform important functions in liver diseases. This review will focus on liver diseases (drug-induced liver injury, hepatic ischemia-reperfusion injury, liver fibrosis, acute liver failure, and hepatocellular carcinoma) and summarize the therapeutic potential of exosomes from different cell sources in liver disease.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansCarcinoma, HepatocellularLiver NeoplasmsLiver CirrhosisExosomes

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.